Olanzapine poisoning in patients treated at the National Poison Control Centre in Belgrade, Serbia in 2017 and 2018: a brief review of serum concentrations and clinical symptoms

The study included 61 incidents of olanzapine poisoning in 60 patients admitted to the emergency room of the NPCC in 2017 to 2018 (one patient was admitted on two occasions). Their blood was taken as part of standard diagnostic procedure and medical treatment in accordance with the Declaration of Helsinki and the procedure approved by the Ethics Committee of the Military Medical Academy.

To determine olanzapine concentrations in the serum, we developed and validated an in-house liquid chromatography with electrospray ionisation mass spectrometry (ESI-LC/MS) method using a Micromass ZQ2000 ESI-LC/MS System (Waters Corporation, Milford, MA, USA). Olanzapine was separated from matrix compounds on the XTerra C₁₈ column (3.5 μm, 4.6×150 mm) with mobile phase at 30 °C, which was a mixture of 5 mmol/L ammonium formiate (pH 3.5) and acetonitrile mixed in gradient mode. The analytical conditions for the mass spectrometric detector were: capillary voltage 3 kV, ion source temperature 125 °C, desolvation temperature 430 °C, desolvation nitrogen flow 400 L/h, and nitrogen flow on the cone 50 L/h. Olanzapine was determined at m/z 313.

In 2017, 15 patients (10 women and 5 men) had olanzapine concentrations in therapeutic range, and 16 in toxic and even lethal range (15 women and 1 man). In 2018, 19 patients (17 women and 2 men) had therapeutic and 11 (7 women and 4 men) toxic olanzapine serum concentrations. The average ingested dose was 280 mg (35–1680 mg) and average time from ingestion to olanzapine determination was 10 h (2–24 h). Most patients had no or mild clinical symptoms of tachycardia and hypotension.

Twenty-eight patients were hospitalised for acute poisoning, while others were discharged after ambulatory treatment. One patient required mechanical ventilation and one was intubated. On admission, 16 patients were in a coma, and 12 presented with mild disturbances of consciousness (7 with sopor and 5 with somnolence). Thirteen had complications like bronchopneumonia and rhabdomyolysis, one developed acute renal failure, and one leucopoenia. According to the Poisoning Severity Score (PSS) proposed by Persson et al. (15), five of the 28 hospitalised patients had mild poisoning (PSS 1), eight pronounced or prolonged poisoning signs or symptoms (PSS 2), 14 severe signs or symptoms (PSS 3), and one patient died (PSS 4). Mean hospitalisation lasted 6.9±6.4 days (2–28 days).

Thirty-four patients (15 in 2017 and 19 in 2018) had serum olanzapine concentration in the therapeutic range, and 27 above the 0.1 mg/L threshold (16 in 2017 and 11 in 2018) (Figure 1). Table 1 lists patients with serum olanzapine concentrations above the lethal threshold of 1 mg/L. Three recovered after therapy, and one died. Patient 2 was admitted to the Emergency Department for overdose twice in three months, first time, allegedly, with 1680 mg. After the second poisoning (ingested dose unknown), olanzapine was determined once a day over the four days of hospitalisation (Figure 2).

Figure 1

Figure 2

Patient 3, a 59-year-old woman who ingested a much lower olanzapine dose (560 mg) and had much lower serum concentration on admission, which peaked on day 5 in the hospital (Figure 3), had severe hypotension and did not respond to supportive and inotropic therapy (dopamine). Intravenous lipid emulsion had transitory positive effects on consciousness and hypotension, but complications with bronchopneumonia and acute renal failure eventually resulted in death 18 days after admission. She combined olanzapine with other drugs prescribed for her standard psychiatric therapy, including clozapine (1000 mg), zolpidem (300 mg), lamotrigine (unknown dose), and midazolam (990 mg). Table 2 shows her serum concentrations of these drugs throughout hospitalisation.

Figure 3

In contrast, one 50-year-old patient presented with severe poisoning after ingesting “only” 120 mg of olanzapine and with initial serum concentration of 0.4 mg/L (Figure 4). He was in a coma, his level of consciousness fluctuated, and had tachycardia and hypotension, followed by complications of severe leucopoenia/ neutropenia, bronchopneumonia (required mechanical ventilation), and rhabdomyolysis (CK 1648 IU/L), whereas renal function remained normal. The patient’s condition was critical for two days after admission, and he was treated with granulocyte colony stimulating factor (G-SF) and antibiotics for febrile neutropenia. Eventually, he completely recovered and was discharged on day 12 of hospitalisation.

Figure 4

Figure 5 shows creatine phosphokinase (CK) levels measured in hospitalised patients. Thirteen patients had normal CK levels (200 IU/L for women and 300 IU/L for men), and 15 above the normal range, eight of whom higher than 1000 IU/L (the highest was 15920 IU/L). High CK points to rhabdomyolysis caused by olanzapine overdose, probably due to antagonism with serotonin, dopamine, histamine, and α1 adrenergic receptors. Its main complication can be acute renal failure (9). Keyal et al. (10) described a case of olanzapine poisoning after ingestion of 400 mg which resulted in CK level of 5780 IU/L on admission. Most of our patients, however, had normal renal function. Acute renal failure was observed in one patient with severe hypotension and CK of 3250 IU/L.

Figure 5

All hospitalised patients received nonspecific detoxification, symptomatic and supportive treatment, including low molecular heparin. The female patient who was admitted in a coma and had high serum olanzapine concentration (2.44 mg/L, see Table 1) after reportedly ingesting 1680 mg of olanzapine was also intubated and received 20 % lipid emulsion solution for hypotension, which is in line with earlier reports (8, 16, 17). Heart pressure was restored, and serum olanzapine dropped after four days (Figure 2) but remained in the lethal range. Complications that followed her severe poisoning included bilateral pneumonia and rhabdomyolysis, yet she fully recovered and was discharged from the hospital after 20 days.

Our findings seem to confirm literature reports of no correlation between clinical findings and ingested olanzapine doses or serum concentrations. Most of our patients had typical clinical signs and symptoms, which were resolved with supportive therapy even in severe cases in which olanzapine concentrations are potentially lethal (>1 mg/L). The case in point is our patient 2, who overdosed with 1680 mg on first admission, yet her serum concentration was lower than in our male patient (3.40 mg/L), who reportedly ingested over ten times lower dose (150 mg). Similar findings were reported by Arora et al. (7), who presented a case of a patient who ingested 1600 mg and required minimal therapy. There are reports of patients surviving and completely recovering from an overdose with 800 mg of olanzapine and serum concentration of 0.991 mg/L or overdosing with 550 mg and 280 mg which led to serum concentrations of 0.815 mg/L and 0.41 mg/l, respectively (3, 18, 19, 20).

The highest serum olanzapine concentration in our study of 3.4 mg/L was found in a 26-year-old male patient, who reportedly ingested about 150 mg and presented deeply somnolent and with tachycardia (130 bpm). Having received non-specific supportive therapy, he totally recovered after only two days. In contrast, our female patient 3, who reportedly took only a third of the dose taken by our patient 2 of 1680 mg, and whose serum concentration was lower than in other two severe cases (1.53 mg/L) died from complications. However, she also took high doses of clozapine, zolpidem, midazolam, and lamotrigine, which probably contributed to prolonged coma, complications, and death. This is in line with case reports of prolonged (cardio)toxicity and seizures, when olanzapine was taken with propranolol and amlodipine (21) or citalopram (22).

The main limitation of our study is its retrospective design, which is liable to inaccuracies in documented risk assessment. However, all data were double-checked and estimated independently by two experienced toxicologists. Another potential limitation is that information about ingested doses was mostly given by the patients or persons who accompanied them on admission, but all poisonings were confirmed by serum analysis.

Our findings confirm that there is no clear relationship between ingested olanzapine dose, its serum levels, and severity of symptoms. As there is no specific antidote for olanzapine poisoning, treatment should start with detoxification and continue with supportive therapy until symptoms are resolved.